Patient Case: Reducing The Risk for Adverse Events in a T2DM Patient with HFrEF, CKD, and Existing ASCVD
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
The advent of SGLT-2 inhibitors and GLP-1 RAs to address cardiorenal risk in patients with and without type 2 diabetes, has opened up new avenues of prevention and treatment. However, individualizing the vast amount of evidence to patient care remains challenging. During this case, you will have a chance to explore treatment decisions to decrease overall cardiorenal risk in a complex patient, accompanied by expert commentary and brief review of evidence with SGLT-2is and GLP-1 RAs across cardiovascular outcomes trials.